Back HIV/Hepatitis Coinfection

Coinfection

Antiretroviral Therapy Reduces Liver Decompensation Risk in HIV/HCV Coinfected Patients

HIV positive people with hepatitis C coinfection who start combination antiretroviral therapy (ART) are less likely to develop decompensated liver disease, or liver failure, according to a study published in the March 1, 2014, edition of Clinical Infectious Diseases. These findings offer further support for early ART initiation for people with viral hepatitis.

alt

Read more:

Antiretrovirals Reduce Liver Decompensation in HIV/HCV Coinfected

Starting antiretroviral therapy (ART) reduces the likelihood that HIV positive people coinfected with hepatitis C virus (HCV) will develop decompensated liver disease, according to a report published in the November 27, 2013, advance edition of Clinical Infectious Diseases.

alt

Read more:

IDWeek 2103: Predicting Response to Acute Hepatitis C Treatment for HIV/HCV Coinfected People

HIV/HCV coinfected people with higher HCV viral load, lower CD4 T-cell counts, older age, and unfavorable IL28B status may not respond as well to interferon-based treatment for acute hepatitis C and may benefit from adding a direct-acting antiviral agent, researchers reported at the 2nd IDWeek meeting last week in San Francisco.

alt

Read more:

AASLD 2013: Faldaprevir + Interferon/Ribavirin Leads to Early Sustained Response for HIV/HCV Coinfected

The HCV protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV positive people coinfected with genotype 1 hepatitis C in the STARTVerso4 trial, according to a poster presented at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

IDWeek 2013: Liver Fibrosis Linked to Immune Activation in HIV/HCV Coinfected Women

CD4 and CD8 T-cell activation were found to be associated with biomarkers of liver fibrosis among HIV/HCV coinfected women, suggesting that immune activation related to persistent HIV infection may play a role in liver disease progression, researchers reported at the Second IDWeek conference this week in San Francisco.

alt

Read more:

AASLD 2013: Sofosbuvir + Ribavirin Produces Sustained Response in 76% of GT 1 HIV/HCV Coinfected Patients

An interferon-free regimen of sofosbuvir plus ribavirin taken for 24 weeks cured three-quarters of previously untreated HIV positive people coinfected with hepatitis C virus (HCV) genotype 1, while 12 weeks of treatment cured 88% and 67% of those with genotypes 2 or 3, according to findings from the Phase 3 PHOTON-1 study presented this week at the 64th AASLD Liver Meeting in Washington, DC.

alt

Read more:

ICAAC 2013: Treatment of HCV Genotypes 2/3 in HIV/HCV Coinfected People

HIV/HCV coinfected patients, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV negative people to pegylated interferon plus ribavirin after taking into account other factors associated with poor treatment response, according to an Italian study presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver. Advanced liver fibrosis was common in the coinfected group, supporting the need for early treatment.

alt

Read more:

AASLD 2013: High Response Rates with Telaprevir Triple Therapy for HIV+ Men with Acute Hepatitis C

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and improves sustained response rates for HIV positive men with acute hepatitis C virus (HCV) infection, according to a presentation yesterday at the at the 64thAASLD Liver Meeting in Washington, DC.

alt

Read more:

ICAAC 2013: Interferon Response Reduces Liver Disease and Death in HIV/HCV Coinfected

Effective interferon-based therapy that produces sustained virological response (SVR) led to significant reductions in liver decompensation, HIV disease progression, and both overall and liver-related mortality among HIV/HCV coinfected patients, according to a presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver.  

alt

Read more: